“Equipping clinicians with essential operational and leadership skills empowers them to engage meaningfully with health systems and regulatory bodies...,” - #ACCPresident Christopher Kramer MD & Drs. Andrew Miller & C. Michael Valentin. #JACC Leadership Page ➡️ bit.ly/4kKfZOW

In the midst of so much hypes around us, probably a very correct & balanced description for #CAC & #PowerOfZero 👇 ⁦Michael J. Blaha⁩ ⁦Ron Blankstein⁩ ⁦Roger Blumenthal⁩ This Test Can See a Heart Attack in Your Future - The New York Times nytimes.com/2025/07/26/hea…

HFrEF ARNI+BB+MRA+SGLT2i Extend median survival by 7-11 YEARS Self-pay cash price for all 4 💊 $121 per month Available today

Dr. Gulati and I delve into the SURPASS-CVOT trial, examining whether dual agonism provides superior efficacy over GLP-1 monotherapy, and discuss what this means for the future of obesity research.

Truly an incredible day and experience at the ASPC Prevention Academy! Such a well thought program and so lucky to have been part of it as a trainee! AJPC #ASPC2025

Live at #ASPC2025? Swing by the Expo Room and get your Lp(a), ApoB, lipid panel, and hsCRP—all from a single, painless capillary sample! A novel, patient-friendly approach to advanced risk screening—only at ASPC. Don’t miss it! #CVDprevention #CardioTwitter

Now Dr. Navar debates that ApoB should be measured over LDL 🫀 Apo B & LDL can be discordant but ApoB identified risk greater than LDL 🫀 ApoB is a Better assay, don’t need to fast & LDL is not that accurate 🫀Guidelines say check in MetSyn because discordant 🫀ESC says ApoB ⭐️

Lipoprotein(a) is finally getting national attention. Our founder Katherine Wilemon (Katherine Wilemon) and Family Heart Ambassador Brian Farrington share their stories in this powerful The Washington Post piece on this underrecognized genetic risk. #KnowLpa washingtonpost.com/health/2025/08…

As rates of obesity and related metabolic disorders continue to rise globally, the need for a more effective, integrated approach to care has never been greater. Join our webinar as we explore the EAS Consensus Statement that tackles this urgent issue head-on - introducing a

☝️LDL-C: No myths. No safe zone. 📉 Risk is proportional. 📉 The lower, the better. 📉 Regression starts at 50–70 mg/dL. 👉Lower LDL-C → Fewer events → Reversed disease. Not opinion. Science. European Atherosclerosis Society

🔴🔴2025 AHA/ACC Hypertension Guideline – Key Clinical Insights for Practice #Hypertension #Cardiology #HeartHealth #BPControl 1️⃣ BP <130/80 mmHg for all adults 🩺 Primary goal for prevention of #CVD, stroke, dementia, CKD, and mortality. Individualize for frailty, pregnancy, or

Editorial: The SCOT-HEART 2 substudy shows that CCTA screening for subclinical atherosclerosis better motivates lifestyle and therapy adherence than traditional risk scores, though long-term impacts on outcomes are unclear. ja.ma/4mzhp00

“We do not prevent atherosclerosis, we manage its consequences” what a powerful viewpoint at this stage by Michael D. Shapiro and Eugene Yang . How much more effort we need to invest for identifying risk early to truly prevent disease. This graphic says it all! Great read and a

👶💊 Statins in pregnancy 🇳🇴 805k pregnancies (2005–2018) 📊 No ↑ risk of any, major, or minor congenital malformations with 1st-trimester statin use ✅ Statins unlikely to be major teratogens 🫀 For women at high CV risk (ie HoFH), benefits likely outweigh potential risks

Released in advance of #ESCCongress The Lancet Reg Health-Europe our paper from the series: Reducing inequalities in cardiovascular disease: focus on marginalized populations considering #ethnicity and #race #CVD #CardioTwitter Presented at European Society of Cardiology on August 29 📎 tinyurl.com/Mgulat

The vast majority of patients with HFpEF have cardiometabolic disease driven by adipose tissue at the core. Lines of evidence continue to support this adipokine hypothesis. The inimitable Milton Packer provides a deeper understanding of the evidence in this timely perspective

Practice-changing meta-analysis presented by ⁦Marco Valgimigli⁩ at #ESCCongress2025 and published in ⁦The Lancet⁩.

The AQUATIC trial may be the most definitive trial of #ESCCOngress The common combo of ASA and OAC for pts with CAD/stent and AF is clearly been harming people. Lots. MACE worse, Death worse, Bleeding way worse. STOP THE ASA when on OAC nejm.org/doi/full/10.10…

A new clinical obesity definition — focused on body fat, not just BMI — is now being implemented in preventive cardiology clinics. Practical steps towards individualized, precision care. Read more: ow.ly/ETE550WRlVY #ObesityMedicine #PreventiveCardiology #PrecisionHealth

The recommendation for the use of omega 3 polyunsaturated fatty acids from 2019 has changed in the Focussed Update by now explicitly stating that only high-dose icosapent ethyl should be considered for high-risk or very high-risk patients with elevated triglyceride levels. The